Corient Capital Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Corient Capital Partners’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$30K	Hold	14,913	–	–	﹤0.01%	663
2022 Q2	$30K	Buy	+14,913	New	+$25.8K	﹤0.01%	678

Other funds holding SRNE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Corient Capital Partners's SRNE Position: Q3 2022 in Review

Corient Capital Partners held its Sorrento Therapeutics, Inc. (SRNE) position steady in Q3 2022 at 14,913 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #663.

Corient Capital Partners first reported a position in SRNE in Q2 2022 and has held it in 2 quarters since. 233 funds tracked by Wall St. Rank hold SRNE as of Q3 2022.

Corient Capital Partners held 14,913 shares of Sorrento Therapeutics, Inc. worth $30K as of Q3 2022.
Corient Capital Partners left its Sorrento Therapeutics, Inc. share count unchanged in Q3 2022.
Sorrento Therapeutics, Inc. made up ﹤0.01% of Corient Capital Partners's portfolio in Q3 2022, its #663 holding.
Corient Capital Partners first reported a position in Sorrento Therapeutics, Inc. in Q2 2022 and has held it in 2 quarters since.
233 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.